Micro-Coring Revolutionized: Cytrellis' Denise Dajles, DEng, MSc, on Evolving Skin Treatments with Ellacor 2.0

Dermatology Times recently spoke with Denise Dajles, DEng, MSc, the newly-appointed president and CEO of Cytrellis Biosystems, Inc., about the launch of the ellacor 2.0 system.

Cytrellis is known for its approach to medical aesthetic solutions, particularly with the introduction of the ellacor system featuring Micro-Coring technology. The company has completed a fresh financing round and released ellacor 2.0.¹

This next-generation device represents a shift toward minimally invasive aesthetic procedures, with advancements based on insights from thousands of procedures conducted since the system’s initial FDA clearance in 2021.²

The First and Only Minimally Invasive Skin Removal Solution

The ellacor system with Micro-Coring technology is an FDA-cleared device that targets moderate to severe wrinkles in the mid and lower face. Unlike traditional surgical options or thermal energy treatments, ellacor uses hollow needles to remove up to 8% of skin in a single in-office procedure. This minimally invasive approach stimulates the body’s natural healing response, leading to significant collagen regeneration and wrinkle reduction—all without scarring.

“With ellacor 2.0, we’ve incorporated valuable feedback from both practitioners and patients to optimize every aspect of the treatment,” Dajles said. “This includes improved needle design for better and faster coring, enhanced software for guided procedures, and comprehensive protocols to ensure consistent outcomes.”

Advancements in ellacor 2.0

Cytrellis has refined the ellacor system with a suite of updates aimed at enhancing efficiency, reducing downtime, and improving patient outcomes. Key enhancements include:

• Improved Needle Cartridge Design: The updated needle system enables faster, more precise coring, reducing procedure time by approximately 35%.
• Enhanced Software: New software guides practitioners through the procedure, ensuring better consistency and ease of use.
• Comprehensive Protocols: Standardized recommendations for pre- and post-procedure care ensure optimal results for a wider range of patients.

Dajles emphasized that the updates reflect a commitment to listening to providers and patients. “We’ve reduced downtime by 60%, allowing patients to return to their daily activities more quickly while maintaining high satisfaction rates among both patients and practitioners,” she noted.

Clinical Efficacy and Industry Response

Clinical studies of ellacor technology have shown up to 90% improvement in the appearance of fine lines and wrinkles. The system’s non-thermal, mechanical skin removal process provides a safer and more predictable alternative to traditional surgical procedures, making it an attractive option for patients seeking effective but minimally invasive treatments.

Dajles described the enthusiastic response from dermatology and plastic surgery practices: “Our users appreciate that ellacor 2.0 incorporates their feedback, and they’re seeing the benefits in both the streamlined procedure and improved outcomes.”

References

1. Cytrellis Biosystems launches updated next-generation skin removal treatment ellacor 2.0, fueled by new leadership and financing. News release. Globe Newswire. January 7, 2025. Accessed January 20, 2025. https://www.globenewswire.com/news-release/2025/01/07/3005404/0/en/Cytrellis-Biosystems-launches-Updated-Next-Generation-Skin-Removal-Treatment-ellacor-2-0-fueled-by-new-leadership-and-financing.html
2. Cytrellis announces FDA clearance for breakthrough Ellacor micro-coring technology. PR Newswire. July 27, 2021. Accessed January 20, 2025. https://www.prnewswire.com/news-releases/cytrellis-announces-fda-clearance-for-breakthrough-ellacor-micro-coring-technology-301341572.html